# US 2016/0252519 A1 · In-vitro method for determining fate of polypeptide variant

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0252519 A1
- Document ID: US20160252519A1
- Status: Published application
- Kind: A1
- Application number: 15/030,237
- Filed: 2014-10-15
- Published: 2016-09-01
- Earliest claimed: 2013-10-18
- Assignees: Dr. Reddy's Laboratories, Inc.
- Applicants: Dr. Reddy's Laboratories Limited
- Inventors: Rajesh MEDISETTY; Lella RAVI KUMAR; Sridevi KHAMBHAMPATY
- Web page: https://patentgrep.com/patent/US20160252519A1

## CPC

- G01N 33/6854: {Immunoglobulins}
- C07K 16/065: {Purification, fragmentation}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention discloses an in-vitro method for determining the fate of protein variants upon administration to a subject. Also provided is a means for establishing comparability between two or more distinct therapeutically effective preparations of the same therapeutic protein.

## Claims

### Claim 1

A Method of determining polypeptide variants of a polypeptide preparation administered to a subject, comprising;
a) isolating serum or plasma from a subject
b) depleting immunoglobulin from the said serum or plasma,
c) spiking the immunoglobulin depleted serum or plasma with the therapeutically effective polypeptide preparation
d) incubating the spiked serum or plasma of step c for a period of time
e) isolating the polypeptide and variants thereof from the spiked serum or plasma of step d, and
f) quantifying the polypeptide and polypeptide variants isolated in step e.

### Claim at position 2 (depends on 1)

2). The polypeptide preparation as in claim 1, is a therapeutic polypeptide preparation.

### Claim at position 3 (depends on 2)

3). The therapeutic polypeptide preparation as in claim 2, includes immunoglobulin and non-immunoglobulin preparation.

### Claim at position 4 (depends on 1)

4). The polypeptide variants as in claim 1, are selected from the variants group consisting of charge variants and glycovariants

### Claim at position 5

5). An in-vitro method for demonstration of clinical significance of a polypeptide variant of administered polypeptide variants, comprising;
a) Isolating serum or plasma from a subject
b) depleting immunoglobulin from the said serum or plasma
c) spiking the immunoglobulin depleted serum or plasma with the therapeutically effective polypeptide preparation
d) incubating the spiked serum or plasma of step c for a period of time
e) isolating the polypeptide and variants thereof from the spiked serum or plasma of step d, and
f) quantifying the polypeptide and polypeptide variants isolated in step e.
